Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.97 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.97 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.97 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.97 |
| ▸ | HTT | P42858 | 5/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.69 |
| ▸ | MAPT | P10636 | 2/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.69 |
| ▸ | GAA | P10253 | 3/20 | 0.68 |
| ▸ | LDHA | P00338 | 1/20 | 0.64 |
| ▸ | ALPG | P10696 | 1/20 | 0.62 |
| ▸ | EGFR | P00533 | 4/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.61 |
| ▸ | APP | P05067 | 2/20 | 0.61 |
| ▸ | GALR3 | O60755 | 2/20 | 0.56 |
| ▸ | NR2F2 | P24468 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | ACP1 | P24666 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31197370 | 0.98 | LMNA (1.00) | LMNASMN1; SMN2S1PR2NPSR1HTT | |
| SCHEMBL15923566 | 0.98 | LMNA (1.00) | LMNASMN1; SMN2S1PR2NPSR1HTT | |
| Hydrochloric Acid SCHEMBL8522254 | 0.98 | SMN1; SMN2 (0.94) | LMNASMN1; SMN2S1PR2NPSR1HTT | |
| SCHEMBL15922842 | 0.98 | LMNA (1.00) | LMNASMN1; SMN2S1PR2NPSR1HTT | |
| SCHEMBL11266817 | 0.91 | LMNA (0.85) | LMNASMN1; SMN2S1PR2NPSR1HTT | |
| SCHEMBL15923281 | 0.91 | SMN1; SMN2 (0.85) | LMNASMN1; SMN2S1PR2NPSR1HTT | |
| SCHEMBL11251521 | 0.91 | SMN1; SMN2 (0.85) | LMNASMN1; SMN2S1PR2NPSR1HTT | |
| SCHEMBL11247766 | 0.91 | SMN1; SMN2 (0.85) | LMNASMN1; SMN2S1PR2NPSR1HTT | |
| SCHEMBL11245701 | 0.91 | LMNA (0.85) | LMNASMN1; SMN2S1PR2NPSR1HTT | |
| SCHEMBL15923231 | 0.89 | SMN1; SMN2 (0.82) | LMNASMN1; SMN2S1PR2NPSR1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318932-B2 | Process for producing 4-aminoquinazoline compound | UBE INDUSTRIES, LTD. (JP) | 2012-11-27 | — | — | US | claimed |
| EP-1481971-B1 | PROCESS FOR PRODUCING 4-AMINOQUINAZOLINE COMPOUND | UBE INDUSTRIES (JP) | 2011-11-16 | — | — | EP | claimed |
| WO-2011131610-A1 | HEAT TRANSFER MEDIUM BASED ON SULPHUR AND USE OF THE HEAT TRANSFER MEDIUM | SIEMENS AKTIENGESELLSCHAFT (DE) | 2011-10-27 | — | — | WO | claimed |
| US-20090171083-A1 | PROCESS FOR PRODUCING 4-AMINOQUINAZOLINE COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2009-07-02 | — | — | US | claimed |
| US-20050130995-A1 | Chlorinating quinazolin-4-one in solvent in presence of a base; then reacting with an amine compound | UBE INDUSTRIES, LTD. (JP) | 2005-06-16 | — | — | US | claimed |
| EP-1481971-A1 | PROCESS FOR PRODUCING 4-AMINOQUINAZOLINE COMPOUND | Ube Industries, Ltd. (JP) | 2004-12-01 | — | — | EP | claimed |
| EP-0954315-A2 | USE OF QUINAZOLINE DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT IN THE TREATMENT OF HYPERPROLIFERATIVE SKIN DISORDERS | Sugen, Inc. (US) | 1999-11-10 | — | — | EP | claimed |
| WO-1998010767-A9 | USE OF QUINAZOLINE DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT IN THE TREATMENT OF HYPERPROLIFERATIVE SKIN DISORDERS | — | 1998-07-02 | — | — | WO | claimed |
| WO-1998010767-A2 | USE OF QUINAZOLINE DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT IN THE TREATMENT OF HYPERPROLIFERATIVE SKIN DISORDERS | SUGEN, INC. (US) | 1998-03-19 | — | — | WO | claimed |
| CN-111741954-B | Novel benzimidazole compounds and derivatives as EGFR inhibitors | 勃林格殷格翰国际有限公司 | 2024-04-02 | — | — | CN | disclosed |
| CN-114007698-B | Macrocyclic compounds and derivatives as EGFR inhibitors | 勃林格殷格翰国际有限公司 | 2024-01-09 | — | — | CN | disclosed |
| EP-4237423-A1 | SUBSTITUTED 1H-PYRAZOLO[4,3-C]PYRIDINES AND DERIVATIVES AS EGFR INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2023-09-06 | — | — | EP | disclosed |
| CN-116507627-A | Substituted 1H-pyrazolo [4,3-C ] pyridines and derivatives as EGFR inhibitors | 勃林格殷格翰国际有限公司 | 2023-07-28 | — | — | CN | disclosed |
| EP-3755694-B1 | NEW BENZIMIDAZOLE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2023-04-05 | — | — | EP | disclosed |
| EP-1147093-A1 | SUBSTITUTED BICYCLIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | Pfizer Products Inc. (US) | 2001-10-24 | — | — | EP | disclosed |
| US-6284764-B1 | ANTIPROLIFERATIVE AGENT | PFIZER INC. | 2001-09-04 | — | — | US | disclosed |
| WO-2000044728-A1 | SUBSTITUTED BICYCLIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PRODUCTS INC. (US) | 2000-08-03 | — | — | WO | disclosed |
| EP-0954315-A2 | USE OF QUINAZOLINE DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT IN THE TREATMENT OF HYPERPROLIFERATIVE SKIN DISORDERS | Sugen, Inc. (US) | 1999-11-10 | — | — | EP | disclosed |
| WO-1998010767-A9 | USE OF QUINAZOLINE DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT IN THE TREATMENT OF HYPERPROLIFERATIVE SKIN DISORDERS | — | 1998-07-02 | — | — | WO | disclosed |
| WO-1998010767-A2 | USE OF QUINAZOLINE DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT IN THE TREATMENT OF HYPERPROLIFERATIVE SKIN DISORDERS | SUGEN, INC. (US) | 1998-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090171083-A1 | PROCESS FOR PRODUCING 4-AMINOQUINAZOLINE COMPOUND | HRH4, CYP3A4, HRH3 | LMNA 4832/4885SMN1; SMN2 4869/4885S1PR2 4388/4885 |
| US-20050130995-A1 | Chlorinating quinazolin-4-one in solvent in presence of a base; then reacting with an amine compound | HRH4, HRH3, H1-4 | LMNA 4755/4885SMN1; SMN2 4852/4885S1PR2 4353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.